Donor T-cells can provide a graft-versus-leukemia effect and help to promote donor engraftment after allogeneic BMT; however, these benefits can be outweighed by the ability of the cells to induce life-threatening GVHD. Photochemical treatment (PCT) of T-cells with S-59 psoralen and long-wavelength UV-A light can inhibit their proliferative capacity and significantly decrease their ability to induce acute GVHD after allogeneic BMT. PCT donor T-cells have been shown to facilitate donor engraftment in a myeloablative BMT model. In this study, we examined whether donor T-cells subjected to PCT ex vivo could retain the ability to facilitate engraftment or increase donor chimerism after nonmyeloablative BMT or after establishment of mixed hematopoietic chimerism. In a transplantation model in which mice were conditioned for BMT with sublethal (600 cGy) TBI, an infusion of PCT donor T-cells was unable to facilitate engraftment of donor BM. A BMT model was used in which a mixture of allogeneic and syngeneic marrow cells was infused into lethally irradiated recipients for establishment of mixed hematopoietic chimerism. The goal was to determine whether PCT donor splenocytes could increase levels of donor chimerism. Recipients of splenocytes treated with UV-A light only (no S-59 psoralen) and given at the time of BMT or in a donor lymphocyte infusion (DLI) had significantly higher levels of donor chimerism than did recipients of BM only. Although PCT donor splenocytes given at the time of BMT modestly increased donor chimerism, PCT donor splenocytes given in a DLI did not increase donor chimerism. A nonmyeloablative BMT model was employed for determining whether DLI given relatively late after BMT could increase donor chimerism. Recipient mice were conditioned for BMT with a combination of low-dose TBI (50 or 100 cGy) and anti-CD154 (anti-CD40L) monoclonal antibody for achievement of low levels of mixed chimerism. When control mixed chimeras were given a DLI 71 days after BMT, donor chimerism was significantly increased. In contrast, PCT of the donor cells eliminated the ability of the cells to increase donor chimerism after infusion. Together results from these 3 distinct BMT models indicate that PCT of donor T-cells significantly inhibited the ability of the cells to facilitate donor engraftment after nonmyeloablative BMT or to increase donor chimerism in mixed hematopoietic chimeras when the cells were administered in a DLI.
INTRODUCTION
Allogeneic bone marrow transplantation (BMT) is currently used in the treatment of a variety of hematologic malignant diseases and nonmalignant hematologic disorders. The conventional high-dose chemotherapy and radiation used to condition patients for allogeneic BMT are highly toxic for both hematologic and nonhematologic tissues. For this reason, less toxic nonmyeloablative conditioning regimens that result in the establishment of mixed chimerism have become attractive. Less toxic conditioning regimens allow transplantation in the care of patients who would not be eligible to receive high-dose conditioning. The establishment of mixed chimerism can facilitate development of donor-host tolerance so that the patient will more readily accept a solid organ transplant. Low levels of donor chimerism may be sufficient to correct certain hematologic disorders, such as sickle cell disease and chronic granulomatous disease [1] . In the case of hematologic malignant diseases, mixed chimerism may create a setting in which donor lymphocyte infusion (DLI) can be given later to eradicate residual tumor and result in the conversion to complete donor chimerism [2] .
Donor T-cells given in DLI can increase donor chimerism and provide a graft-versus-tumor (GVT) effect with a lower risk of graft-versus-host disease (GVHD) than if given at the time of BMT, possibly owing to immunoregulatory mechanisms [3, 4] . However, despite a lower incidence of severe disease, GVHD is still one of the major complications of DLI. Thus an ongoing challenge for clinicians has been to reduce the ability of donor T-cells to induce GVHD after BMT or DLI yet maintain their ability to facilitate or increase donor engraftment and mediate a GVT effect. Several strategies have been employed in attempts to accomplish this goal, including insertion of suicide genes [5, 6] , administration of fixed low numbers of donor T-cells in the BMT graft [7] , selective administration of T-cell subsets [8] , incremental DLI [9] , and ex vivo γ irradiation [10] . It is still unclear whether any one approach is superior to the others.
PCT of donor T-cells with S-59 psoralen and longwavelength UV-A light has been used in an experimental BMT model to limit GVH potential without eliminating GVT reactivity [11] . This method for controlling T-cell reactivity is particularly attractive because it is relatively simple and inexpensive. S-59 psoralen reversibly intercalates DNA, but when the S-59-treated DNA is exposed to UV-A light, covalent monadducts form. The result is cross-linked DNA and prevention of DNA replication [12] . Cells treated with particular concentrations of S-59 and UV-A light are incapable of proliferating but can still express activation markers and secrete cytokines [11] . These data suggest that PCT donor T-cells are at least partially functional for a period. In the current study, we examined whether a single infusion of PCT donor cells could facilitate engraftment of donor BM after nonmyeloablative conditioning or increase donor chimerism in a model of mixed chimerism.
MATERIALS AND METHODS

Mice
C57BL/6 (H2 b ), Balb/c (H2 d ), B10.BR (H2 k ), AKR/J (H2 k ), and B6.PL-Thy1 a (H2 b ) mice 6 to 8 weeks of age were purchased from Jackson Laboratories (Bar Harbor, ME). The animals were housed in the Medical College of Wisconsin Animal Resource Center or in a specific pathogenfree facility at the University of Minnesota.
Bone Marrow Transplantation
Bone marrow (BM) was collected from the femurs and tibias of Balb/c, C57BL/6, or B6.PL-Thy1 a donors. Three BMT models were used. In the first, B10.BR recipients were given a sublethal dose of 600 cGy total body irradiation (TBI). Twenty-four hours later, the recipients were given an intravenous (IV) injection of 10 7 T-depleted B6.PL-Thy1 a BM cells admixed with various numbers of PCT or control (UV-A-treated) purified donor T-cells. The BM was depleted of T-cells by treatment with anti-Thy1.2 murine antibody (mAb) (clone 30-H12; American Type Culture Collection, Manassas, VA) and complement (Accurate Chemical and Scientific, Westbury, CT). Donor T-cells were purified from splenocytes by negative selection after incubation with magnet-activated cell separation (MACS) anti-B220-conjugated magnetic beads (Milenyi Biotec, Auburn, CA). The labeled cells were passed through MACS columns to remove B-cells. The resulting population of negatively selected cells comprised 80% T-cells. In the second model, AKR/J recipients were given 1100 cGy TBI and intraperitoneal (IP) injection of a combination of 200 µg anti-TCRαβ mAb (hybridoma H57-597) and 500 µg anti-CD4 mAb (hybridoma GK1.5). One day later, the mice were given an IV injection of a mixture of 6 × 10 6 T-depleted allogeneic C57BL/6 BM and 4 × 10 In the third model, B6 recipients were given a single dose of 50 or 100 cGy TBI. One day later, the mice were given IV injections of 4 × 10 7 non-T-depleted Balb/c BM cells. Bioreactor-derived anti-CD154 mAb (hybridoma MR1) was administered IP (200 µg per injection) from days -1 to 5, then twice weekly until day 14 after BMT [13] . For DLI, chimeras were given a single IV injection of 5 × 10 7 PCT or control (UV-A-treated) Balb/c spleen cells.
For assessment of GVH reactivity, the recipients were followed for body weight changes and mortality. In some experiments, spleens collected from mice were analyzed by flow cytometry to determine CD4:CD8 ratios.
PCT of Cells
S-59 psoralen was provided by Cerus Corp. (Concord, CA) and diluted in sterile distilled water for a stock solution of 1 µM. Splenocytes or purified T-cells were washed by centrifugation and resuspended at 1 to 2 × 10 7 /mL in phosphatebuffered saline solution containing 5% fetal bovine serum. S-59 was added to the cell suspensions at a final concentration of 1 or 2 nM, and the cells were placed in 15-× 60-mm plastic Petri dishes or 75 cm 2 tissue culture flasks at a volume that resulted in a fluid layer of approximately 0.5 cm. The dishes and flasks were placed on a UV-A (320-400 nm) illumination device and exposed to a dose of 3 or 4 J/cm 2 . The cells were washed and prepared for injection. In some experiments, to control for light exposure, cells were exposed to UV-A only (no S-59). In tests for PCT-induced T-cell inactivation, PCT and non-PCT T-cells or splenocytes (0.5 × 10 5 or 2 × 10 5 per well, respectively) were cultured in 3 to 6 microwells containing immobilized anti-CD3 mAb (clone 145-2C11). The microwell plates were cultured at 37°C for 3 to 4 days, and 1 µCi of 3 H-thymidine was added to each well for the final 18 hours of culture. Stimulation of the cultured cells was calculated from the amount of 3 H-thymidine uptake. The combination of 1 nM S-59 plus 4 J/cm 2 UV-A or 2 nM S-59 plus 3 J/cm 2 UV-A typically
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resulted in 90% to 96% inactivation of T-cell proliferation in response to CD3 cross-linking ( Figure 1 ).
Assessment of Engraftment and Chimerism
For assessment of the engraftment status of BMT recipients in the first 2 BMT models (sublethal TBI and mixedchimerism lethal TBI models), recipients were euthanized at various time points after BMT. Individual spleens were collected and processed into single-cell suspensions, and the red cells were eliminated by hypotonic lysis. The cells were stained with combinations of fluorochrome-labeled major histocompatibility complex (MHC) class I-specific mAb (anti-H2K k or anti-H2K b ) and lineage-specific mAb, including anti-CD4, anti-CD8, anti-B220, and anti-Mac-1. In the mixed chimerism model, donor T-cells given as DLI could be identified by staining with a combination of donor MHC class I mAb (anti-H2K b ) and anti-Thy1.1 mAb. All mAbs were purchased from Pharmingen (San Diego, CA).
For chimerism analysis of mice conditioned for BMT with nonmyeloablative TBI and anti-CD154 mAb, the mice were bled by retroorbital venipuncture, and the mononuclear cells were collected after centrifugation over Ficoll medium. The cells were stained with a combination of fluorochrome-labeled MHC class I-specific mAb (anti-H2 b or anti-H2 d for identification of recipient and donor cells, respectively) and lineage-specific mAbs, including anti-CD4, anti-CD8, anti-CD19, and anti-Mac-1 (Pharmingen).
Stained cells were analyzed by flow cytometry with FACScan or FACSCalibur flow cytometers (Becton Dickinson, Mountain View, CA).
Statistics
Engraftment, chimerism values, and CD4:CD8 ratios were compared with the Student t test.
RESULTS
A Single Infusion of PCT Donor Splenocytes Did Not Increase Splenic Donor Chimerism When Given at the Time of BMT or in DLI Soon after BMT
A BMT model was established for examining whether PCT donor T-cells could facilitate the engraftment of donor BM in recipients preconditioned with sublethal TBI. B10.BR recipients were conditioned with 600 cGy TBI then subjected to transplantation of 10 (Table 1) . This mouse was a mixed chimera with a spleen containing 40% donor cells (data not shown). UV-A-only treated donor T-cells increased donor engraftment in a dose-dependent manner, but mice given 1.25 to 5 × 10 6 donor T-cells developed GVHD as indicated by body weight loss (data not shown) and decreased splenic CD4:CD8 ratios (Table 1 ). All mice with engraftment of donor cells, except for 1 mouse that received a dose of 0.6 × 10 6 T-cells, had >90% donor cells in their spleens. The 1 mouse that had less than 90% donor cells was a mixed chimera that had 34% donor cells in its spleen (data not *NA indicates not applicable. †B10.BR recipient mice were conditioned for BMT by treatment with 600 cGy TBI. Twenty-four hours later, the recipients were given 10 7 nucleated B6.PL-Thy1 a BM cells admixed with or without the indicated number of PCT (2 nM S-59 and 3 J/cm 2 UV-A) or UV-A-only treated donor T-cells. ‡Donor engraftment was assessed by flow cytometric analysis of splenocytes stained with B-cell, T-cell, and monocyte lineage-specific cell markers in combination with MHC class I specific markers. The data are the combined results of mice analyzed on days 14, 30, and 100 after BMT (2-6 mice analyzed at each time point). The data were combined because engraftment was stable.
§CD4:CD8 ratios were derived from splenic phenotyping done on day 30 after BMT (3-6 mice analyzed in each group).
||P < .05 compared with the group given no donor T-cells.
shown). Mortality due to GVHD was observed in the groups given 5 × 10 6 (50%), 2.5 × 10 6 (50%), and 1.25 × 10
(33%) donor UV-A-treated T-cells (data not shown).
Mice that received PCT donor T-cells did not have engraftment with donor cells, with the exception of 1 animal that received 5 × 10 6 PCT donor T-cells (Table 1 ). The single mouse with engraftment had only donor cells in the spleen (data not shown). Because facilitation of engraftment was inhibited by PCT, not surprisingly recipients of PCT cells did not develop GVHD as indicated by "normal" splenic CD4:CD8 ratios ( Table 1 ) and maintenance of body weight above pretransplantation levels (not shown).
A model of mixed hematopoietic chimerism induced by combined allogeneic and syngeneic BM infusion was used to determine whether allogeneic PCT donor splenocytes could increase donor chimerism early or later post-BMT. A strategy similar to that used by Sykes et al. [14] was employed. In our study, AKR recipients conditioned with lethal TBI and anti-TCRαβ plus anti-CD4 mAbs were given transplants of a 60:40 mixture of allogeneic donor and syngeneic host BM (10 7 cells total). Recipients of only BM had approximately 40% donor cells in their spleens when examined 50 days after BMT (Table 2) , and all cell lineages were a mixture of donor and host. The thymuses of these mice also contained mixtures of donor and host cells (data not shown).
When a single infusion of 3 × 10 7 donor splenocytes was given on the day of BMT or in DLI on days 7, 14, or 28 after BMT, the mice had significantly higher levels of splenic donor chimerism than did recipients of BM only (Table 2 ). Increased percentages of donor cells were also found in the thymuses of these mice (data not shown). All groups of mice that received an infusion of control (UV-Atreated) donor cells appeared to have increased GVH reactivity as indicated by body weight loss ( Figure 2A ) and decreased lymphoid tissue cellularity (spleens and thymuses) (data not shown). Because the infused T-cells were from Thy1.1 + congenic donors, we could examine splenocytes on day 50 after BMT for the presence of these cells by flow cytometry using a combination of cell-surface markers for Thy1.1 and donor MHC class I (H-2K b ). Significant percentages of infused donor T-cells (5% to 15%) could be detected in the spleens of these mice on day 50 after BMT (Table 2 ). This finding suggested that these cells were playing a role in the induction of GVH reactivity.
As shown in Table 2 , PCT significantly reduced the ability of donor splenocytes given as a DLI early post-BMT to increase donor chimerism. Donor chimerism was modestly greater when PCT donor cells were given at the time of BMT (day 0) than it was in mice given transplants of BM only (56% versus 42%; P = .01). Although the change in donor chimerism was increased significantly, this change was substantially lower than that induced by non-PCT donor T-cells. However, when PCT cells were given as DLI, no increase in donor chimerism was observed. PCT significantly reduced the GVH reactivity of donor cells, as indicated by no mortality (Table 2 ) and stable body weights ( Figure 2B ). These mice also did not have decreased lymphoid tissue cellularity, as was observed in groups given infusions of non-PCT donor cells (not shown). These data indicated that PCT eliminated the GVH capacity of infused donor cells, but the ability of these cells to increase donor chimerism was significantly decreased.
PCT Donor Spleen Cells Given in a DLI Did Not Increase Peripheral Blood Donor Chimerism in a BMT Model of Minimal Myeloablation
A different BMT model was used to confirm results of the previous experiments and to test whether DLI with PCT cells at later times post-BMT could increase donor chimerism. C57BL/6 recipients were conditioned for BMT with a nonmyeloablative dose of TBI (50 or 100 cGy) and anti-CD40L mAb. After transplantation with Balb/c BM, anti-CD40L mAb treatment was continued for 2 weeks. The B6 recipients became long-term stable mixed chimeras *AKR/J recipient mice were conditioned for BMT by treatment with 1100 cGy TBI and anti-TCRαβ mAb plus anti-CD4 mAb. Twenty-four hours later, the recipients were given 6 × 10 6 C57BL/6 BM cells plus 4 × 10 6 AKR/J BM cells. †PCT (1 nM S-59 and 4 J/cm 2 UV-A) or UV-A-only treated B6.PL-Thy1 a donor spleen cells (3 × 10 7 ) were given at the indicated times. ‡Donor engraftment of allogeneic BM was assessed on day 50 after BMT by flow cytometric analysis of splenocytes stained with B-cell, T-cell, and monocyte lineage-specific cell markers in combination with an MHC class I-specific marker.
§The percentages of infused donor T-cells were determined by flow cytometry after spleen cells were stained with a combination of H-2K b -FITC and anti-Thy1.1-PE. Background percentages (1.5% ± 0.3%) were determined from mice that received BM only (no infusion).
||Significantly increased (P < .05) compared with the group given BM only (no donor spleen cells). ¶Significantly increased (P < .05) compared with background (1.5 ± 0.3%). (Table 3 ) with a higher level of chimerism observed in mice conditioned with 100 cGy TBI. A single infusion of 5 × 10 7 control non-PCT donor splenocytes given on day 71 after BMT significantly increased donor chimerism in mice that were analyzed on days 101 and 168 after BMT (Table 3) . Mice given the DLI developed GVHD, but the GVHD was not sufficiently severe to induce mortality by day 168 after BMT (data not shown). The presence of GVHD was reflected by less body weight gain after DLI than occurred in recipients of BM only (Figure 3 ). When the donor cells given as DLI were subjected to PCT, the cells were no longer capable of increasing donor chimerism (Table 3) . Body weight gain after DLI with PCT donor cells was less than in recipients of BM only ( Figure  3 ), but the decreased weight gain was less than that in mice given non-PCT DLI. The body weight curves in conjunction with the clinical appearance of the animals suggested that GVH capacity of the donor cells, as well as chimerismfacilitating capacity, was diminished by PCT. Although the donor splenocytes were treated with a PCT regimen different from that used in the first BMT model, in which the S-59 concentration was increased and the light exposure decreased, the level of donor T-cell inactivation, measured by proliferation in response to immobilized anti-CD3 [11] , was similar with both PCT regimens (Figure 1 ).
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DISCUSSION
Truitt et al. previously demonstrated that PCT donor T-cells could increase donor chimerism after myeloablative conditioning and allogeneic BMT [11] . Similarly, Waller et al. showed that donor lymphocytes treated with ionizing radiation could facilitate donor engraftment without inducing GVHD [10] . Their study was based on previous data that demonstrated ionizing radiation could limit the capacity of lymphocytes to proliferate but still allow for cytotoxic function against tumor cells [15] and preserve veto function against host T-cells [16] . On the basis of these observations, we hypothesized that PCT donor cells could facilitate donor engraftment. Three different MHC-incompatible BMT models were used to examine the ability of PCT donor cells to increase donor chimerism. In the first model, mice were conditioned with sublethal TBI. The result was graft rejection and autologous reconstitution unless donor T-cells were added to the BM graft. In the second model, recipient mice were conditioned with lethal TBI then subjected to transplantation with Table 2 are shown. The data are from mice given 3 ϫ 10 7 nontreated (UV-A) donor spleen cells (A) or PCT donor spleen cells (B) at the time of BMT (day 0) or 7 to 28 days after BMT. Body weight curves for mice given transplants of BM alone (no spleen cells) represent GVH-negative controls. *B6 recipient mice were conditioned for BMT by treatment with 200 µg anti-CD40L mAb (days -1 to 5, then twice weekly to day 14) and either 50 or 100 cGy total body irradiation (TBI) (day -1). For BMT, the recipients were given 4 × 10 7 nucleated Balb/c BM cells. †On day 71 posttransplantation, 5 × 10 7 Balb/c nontreated or PCT spleen cells were given as DLI. For PCT, donor splenocytes were treated with 2 mM S-59 psoralen and 3 J/cm 2 UV-A light. ‡Recipients were bled at the indicated time points for assessment of donor chimerism.
§P < .05 compared with the day 57 BM chimeras conditioned with 50 cGy.
||P < .05 compared with BM chimeras given the same conditioning but no DLI. a mixture of syngeneic and allogeneic BM to achieve mixed hematopoietic chimerism. In the third model, BM recipients were treated with a nonmyeloablative conditioning regimen for establishment of low-level donor chimerism (10% to 27%). Using these models, we tested whether a single infusion of PCT donor cells could increase donor chimerism when the infusion was given at the time of BMT or as a DLI early as opposed to later after transplantation.
In the first model (sublethal TBI with 600 cGy), nontreated donor T-cells facilitated donor engraftment in a doserelated fashion, but PCT donor T-cells lost the ability to facilitate engraftment of donor BM (Table 1 ). In a model of mixed chimerism, when PCT donor splenocytes were given to recipients of mixed syngeneic/allogeneic BM at the time of transplantation, the cells were able to modestly increase donor chimerism in comparison with the results among mice given transplants of BM only (Table 2) . However, the level of donor engraftment achieved by PCT donor splenocytes given at the time of BMT was significantly less than that obtained by administration of non-PCT donor cells (treated with UV-A light only). Both PCT and non-PCT donor T-cells given on the day of BMT persisted in the spleens of infusion-treated mice until day 50 after BMT (Table 2 ), but the percentage of infused cells in the PCT group was significantly lower (P < .05) than that in the non-PCT group. The long-term persistence of a small population of PCT donor T-cells in chimeras that received the cells at the time of BMT is consistent with previous data [11] . In the current study, the long-term persistence of infused donor T-cells correlated with increased donor engraftment. Together the results of these experiments indicate that PCT of donor lymphocytes inhibits their ability to facilitate donor engraftment.
When donor cells were given in a DLI, PCT eliminated their ability to increase donor chimerism in 2 different BMT models. The timing of DLI did not affect the inability of PCT donor cells to increase donor chimerism. DLI was given early post-BMT in 1 model (day 7-day 28 after BMT) and late in the other model (day 71). Administration of non-PCT DLI resulted in GVHD after administration of donor cells, although GVHD was less severe than would be expected if similar numbers of donor cells were given at the time of BMT. These results were not unexpected because previous data showed that the longer DLI is delayed after BMT, the lower is the risk of development of GVHD [17] . PCT did have a beneficial effect in that it significantly reduced or eliminated DLI-induced GVHD, but this effect was not remarkable because the ability of these cells to facilitate engraftment was also significantly inhibited.
The results presented here were different from those previously reported by Truitt and coworkers [11] . We believe the disparities are most likely due to differences in the model systems. One explanation for the inability of PCT donor T-cells to increase donor chimerism when given in DLI, or when given at the time of BMT after nonmyeloablative conditioning, may be that a single infusion of PCT donor cells is not sufficient to overcome established tolerance mechanisms in the DLI setting or host-versusgraft reactivity that remains after nonmyeloablative conditioning. Perhaps multiple infusions of PCT donor cells could overcome such barriers, if present, to facilitate donor engraftment and increase donor chimerism in our models.
The need for increasing donor chimerism after BMT may be most relevant to the treatment of hematologic malignant diseases in which the elimination of residual host tumor in mixed chimeras may be needed to prevent relapse. Previous data showed that the effect of PCT on GVT reactivity was PCT regimen-dependent [11] . On the basis of chimerism results obtained in our experiments, we would speculate that the GVT reactivity of PCT donor cells is diminished. It appears that PCT donor T-cells persist for only a short time in chimeras given a DLI. We did not detect these cells in mice that were analyzed 22 to 43 days after DLI (Table 2) . Because measurable DLI-induced GVT responses in humans sometimes require several weeks, we speculate that longer-term persistence of PCT donor T-cells may be needed to achieve significant GVT reactivity. Multiple infusions of PCT lymphocytes may provide GVT reactivity as well as increase donor chimerism.
In summary, PCT inhibited the ability of donor cells to facilitate donor engraftment or increase donor chimerism post-BMT. Perhaps larger doses of PCT donor splenocytes or PCT CD8 + donor T-cells would be more effective at increasing donor chimerism. Because PCT donor cells lose their capacity to induce GVHD, multiple infusions of these cells may be a better approach to increase donor chimerism. Of concern is whether increased numbers of cells given as multiple infusions would increase the risk of GVHD. The answer may depend on how long PCT-cells are able to persist in vivo. These issues need to be addressed in future experiments.
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